Janet B. McGill
Washington University in St. Louis
212 Papers
924 Citations
Janet B. McGill is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Diabetes mellitus & Medicine. The author has an hindex of 61, co-authored 182 publications.
Chat about Author
Papers
Linagliptin for type 2 diabetes mellitus: a review of the pivotal clinical trials.
TL;DR: Four pivotal trials confirm linagliptin is effective and safe in patients with type 2 diabetes mellitus: the convenience of oral dosing with no requirement for dose adjustment in Patients with renal or hepatic impairment make linaglisptin a valuable option when considering therapies for patients with T2DM.
Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study.
Julio Rosenstock,Vivian Fonseca,Janet B. McGill,Matthew C. Riddle,J.-P. Hallé,Irene Hramiak,P. Johnston,M. Davis +7 more
TL;DR: This study shows no evidence of a greater risk of the development or progression of diabetic retinopathy with insulin glargine vs NPH insulin treatment in patients with type 2 diabetes mellitus.
Fatty Acids and Insulin Modulate Myocardial Substrate Metabolism in Humans With Type 1 Diabetes
Linda R. Peterson,Pilar Herrero,Janet B. McGill,Kenneth B. Schechtman,Zulfia Kisrieva-Ware,Donna Lesniak,Robert J. Gropler +6 more
TL;DR: Type 1 diabetes myocardium has increased MVo2 and is insulin resistant during euglycemia, however, its myocardial glucose and fatty acid metabolism still responds to changes in plasma insulin and plasma FFA levels, which can regulate the intramyocardial fate of fatty acids in humans with type 1 diabetes.
Coverage for Continuous Glucose Monitoring (CGM) for Individuals with Type 2 Diabetes Treated with Non-intensive Therapies: An Evidence-Based Approach to Policy-Making.
Grazia Aleppo,Irl B. Hirsch,Christopher G. Parkin,Janet B. McGill,Rodolfo J. Galindo,Davida F. Kruger,Carol J. Levy,Gregory P. Forlenza,Guillermo E. Umpierrez,George Grunberger,Richard M. Bergenstal +10 more
TL;DR: The benefits of continuous glucose monitoring in individuals with Type 1 diabetes (T1D) and Type 2 diabetes who are treated with intensive insulin regimens are discussed in this article , but despite increasing evidence supporting CGM use for individuals treated with less-intensive insulin therapy or non-insulin medications, insurance coverage is limited or nonexistent.
Protein kinase C β inhibition: the promise for treatment of diabetic nephropathy
TL;DR: Inhibition of protein kinase C β may represent a novel strategy to improve kidney outcomes in patients with diabetes mellitus and large-scale, prospective trials are needed to confirm the safety and potential benefits of ruboxistaurin in patientswith diabetic nephropathy.